Literature DB >> 2189695

Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis.

K Kondo1, M Noguchi, K Mukai, Y Matsuno, Y Sato, Y Shimosato, Y Monden.   

Abstract

Immunohistochemical reactivity with OKT9 (antitransferrin receptor) monoclonal antibody was studied in 58 surgically resected adenocarcinomas of the lung. The cell surface and cytoplasm of the tumor cells were stained in 44 cases (76 percent). The expression of the transferrin receptor (TrfR) in tumor cells was compared with histopathologic prognostic factors, such as TNM factors, degree of histologic differentiation, degree of nuclear atypia, and frequency of mitotic figures. The expression of TrfR showed significant correlation with the degree of histopathologic differentiation (p less than 0.025), degree of nuclear atypia (p less than 0.025), and frequency of mitotic figures (p less than 0.001). However, there was no definite correlation with TNM factors. These results indicate that the expression of the TrfR in pulmonary adenocarcinoma corresponds to the elevated proliferative activity of the tumor cells, and that immunohistochemical reactivity with OKT9 can be used as one of the histopathologic indicators of prognosis of pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189695     DOI: 10.1378/chest.97.6.1367

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

2.  Simultaneous detection of genetic and immunological markers in non-small cell lung cancer: prediction of metastatic potential of tumor.

Authors:  I Zborovskaya; A Gasparian; M Kitaeva; B Polotzky; N Tupitzin; Z Machaladze; S Gerasimov; M Shtutman; M Jakubovskaya; M Davidov; A Tatosyan
Journal:  Clin Exp Metastasis       Date:  1996-11       Impact factor: 5.150

3.  Soluble transferrin receptor and iron status in elderly patients.

Authors:  Franz Böhmer; Thomas Frühwald; Alexander Lapin
Journal:  Wien Med Wochenschr       Date:  2003

Review 4.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

5.  The value of octreotide scintigraphy in patients with lung cancer.

Authors:  D J Kwekkeboom; G S Kho; S W Lamberts; J C Reubi; J A Laissue; E P Krenning
Journal:  Eur J Nucl Med       Date:  1994-10

6.  Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer.

Authors:  Michelle Lenarduzzi; Angela B Y Hui; Shijun Yue; Emma Ito; Wei Shi; Justin Williams; Jeff Bruce; Noriko Sakemura-Nakatsugawa; Wei Xu; Aaron Schimmer; Fei-Fei Liu
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

7.  A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.

Authors:  Megumi Kawamoto; Tomohisa Horibe; Masayuki Kohno; Koji Kawakami
Journal:  BMC Cancer       Date:  2011-08-18       Impact factor: 4.430

8.  Soluble and cell-associated transferrin receptor in lung cancer.

Authors:  A Dowlati; M Loo; T Bury; G Fillet; Y Beguin
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.

Authors:  Ran Liu; Yonglu Wang; Xueming Li; Wen Bao; Guohua Xia; Wei Chen; Jian Cheng; Yuanlong Xu; Liting Guo; Baoan Chen
Journal:  Drug Des Devel Ther       Date:  2015-05-22       Impact factor: 4.162

10.  Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.

Authors:  Artavazd Arumov; Piumi Y Liyanage; Roger M Leblanc; Jonathan H Schatz; Asaad Trabolsi; Evan R Roberts; Lingxiao Li; Braulio C L B Ferreira; Zhen Gao; Yuguang Ban; Austin D Newsam; Melissa W Taggart; Francisco Vega; Daniel Bilbao
Journal:  Cancer Res       Date:  2020-11-11       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.